XiaoLu YiGuan Lands $20 Million In Series Pre-C Financing, Building An Online Services For Chinese Medicine

According to 36KR, inline Chinese Medicine platform XIaoLu YiGuan just received 20 million dollars in Series Pre-C financing. The investment was led by NGP Capital, and the funds will be used to complete the VIE adjustment, expand the AI team and improve technologies.

XiaoLu YiGuan is mainly engaged in the remote diagnosis of Chinese medicine and distributes medicines to patients through the supplier's “smart pharmacy”. Right now, there are already more than 23,000 doctors on the platform and drug sales have reached a few million dollars since 2017.

In the fast few years, XiaoLu YiGuan has gained a lot of data from the patients and doctors. The company is analyzing these data to improve their future diagnosis and other services. Right now, most of XiaoLu YiGuan’s profits come from drug sales.

The combination of Chinese medicine and the Internet actually has a natural advantage, because Chinese medicine mostly just treats chronic diseases, and Chinese medicine often takes a long time to recuperate. That’s why an online platform can save patients’ time and money. XiaoLu YiGuan ensures efficacy through great doctors, quality herbs and accurate data.    

With more than $1Billion under management, NGP specializes in growth-stage investing seeking entrepreneurs building intelligent devices and services connecting everybody and everything. NGP offers market insight, support, a deep network and a global reach spanning the United States, Europe, India and China.